NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Tesla, Inc. (NASDAQ: TSLA)
Class Period: Purchasers of shares between August 7, 2018 and August 17, 2018 and/or who had open short positions or put options for Tesla as of August 7, 2018 or August 8, 2018
Lead Plaintiff Deadline: October 9, 2018
Join the action: http://www.zlk.com/pslra-1/tesla-inc-loss-submission-form?wire=3

About the lawsuit: During the class period, Tesla, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Defendants had not secured funding for the Going-Private Transaction; (2) Musk’s statements that the Going-Private Transaction only required shareholder approval were false since the Going-Private Transaction required approval by the Company’s Board of Directors and even the Board was unaware of the funding referred to by Musk; (3) the status and likelihood of the Going-Private Transaction was misrepresented to the market because financing for it had not been secured and Board approval was required, and (4) as a result of the foregoing, Defendants’ statements about Tesla’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Tesla, Inc. class action contact [email protected].

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE)
Class Period: December 14, 2017 - August 7, 2018
Lead Plaintiff Deadline: October 24, 2018
Join the action: http://www.zlk.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3

About the lawsuit: Ampio Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.

To learn more about the Ampio Pharmaceuticals, Inc. class action contact [email protected].

Sinclair Broadcast Group, Inc. (NASDAQ: SBGI)
Class Period: February 22, 2017 - July 19, 2018
Lead Plaintiff Deadline: October 9, 2018
Join the action: http://www.zlk.com/pslra-d/sinclair-broadcast-group-inc?wire=3

About the lawsuit: Throughout the class period, Sinclair Broadcast Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the merger of Tribune Media Company (NYSE: TRCO) and Sinclair was not in compliance with FCC rules and regulations; (ii) Sinclair was not using its best efforts to eliminate any impediment to regulatory approval; (iii) Sinclair was engaging in non-arm’s length transactions with buyers connected to Sinclair’s controlling shareholders in order to skirt FCC ownership rules; and (iv) that, as a result of the foregoing, Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis.  

On May 8, 2017, Sinclair announced it had entered into an agreement to acquire 100% of the issued outstanding shares of Tribune. On August 3, 2017, Sinclair filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing that the U.S. Department of Justice had requested additional information and documentary material pertaining to the agreement. Then on August 9, 2018, Tribune said it had terminated the deal and was suing Sinclair for breach of contract following the FCC’s determination that Sinclair failed to fully disclose material information about the merger.

To learn more about the Sinclair Broadcast Group, Inc. class action contact [email protected].

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com